{"id":5837,"date":"2024-10-15T04:10:10","date_gmt":"2024-10-15T09:10:10","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5837"},"modified":"2025-06-27T08:34:47","modified_gmt":"2025-06-27T13:34:47","slug":"nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/","title":{"rendered":"Nanoscope anuncia presentaciones en la reuni\u00f3n anual de la Academia Estadounidense de Oftalmolog\u00eda de 2024"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">15 de octubre de 2024<\/span><\/span>\u00a0\u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa de presentaci\u00f3n de solicitudes para la BLA que desarrolla terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que Nanoscope se presentar\u00e1 en el\u00a0<a href=\"https:\/\/aao.apprisor.org\/apsHome.cfm?CFID=2245828&CFTOKEN=901353392bf9903f-A2C6E16B-FB1D-9B2F-19328F49BD5170C1\" target=\"_blank\" rel=\"nofollow noopener\">Reuni\u00f3n anual de la AAO 2024<\/a>\u00a0teniendo lugar\u00a0<span class=\"xn-chron\">18-21 de octubre de 2024<\/span>\u00a0en\u00a0<span class=\"xn-location\">Chicago, Illinois<\/span>, y el asociado\u00a0<a href=\"https:\/\/www.eyecelerator.com\/aao-2024-program\/aao-2024-retina-showcase\" target=\"_blank\" rel=\"nofollow noopener\">Acelerador de ojos en la AAO 2024<\/a>\u00a0y\u00a0<a href=\"https:\/\/retinainnovate.com\/agenda\/\" target=\"_blank\" rel=\"nofollow noopener\">Innovar la retina<\/a>\u00a0reuniones que tienen lugar en\u00a0<span class=\"xn-chron\">17 de octubre<\/span><sup>th<\/sup>, 2024. Los detalles de las presentaciones son los siguientes:<\/p>\n<p><b>T\u00edtulo:\u00a0<\/b>Eficacia y seguridad de la terapia optogen\u00e9tica MCO-010 para la restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida grave de la visi\u00f3n debido a RP: resultados TOPLINE de dos a\u00f1os de un estudio de fase\u00a0<span class=\"xn-money\">2b<\/span>\/3 Ensayo cl\u00ednico aleatorizado y controlado con placebo (RESTORE)<br class=\"dnr\" \/><b>Sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n PA048 (Art\u00edculos originales sobre retina y v\u00edtreo)<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">Domingo 20 de octubre<\/span><sup>th<\/sup>, 2024<br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">14:00 \u2013 15:15 CDT<\/span>\u00a0(En persona, a pedido)<br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>Centro de convenciones McCormick Place, sala S405<br class=\"dnr\" \/><b>Presentador:\u00a0<\/b>Allen Ho, MD, FACS, FASRS, Director de Investigaci\u00f3n de Retina y Codirector del Servicio de Retina en Wills Eye Hospital, y Asesor M\u00e9dico Jefe de Nanoscope Therapeutics, Inc.<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Ho analizar\u00e1 los datos preliminares del estudio RESTORE de Nanoscope, un ensayo cl\u00ednico aleatorizado y controlado (ECA) sobre la terapia con MCO-010 en pacientes con p\u00e9rdida grave de visi\u00f3n debido a retinosis pigmentaria (RP). RESTORE es el primer ECA que demuestra una mejora estad\u00edsticamente significativa de la agudeza visual en esta poblaci\u00f3n de pacientes y constituye una pieza clave en la pr\u00f3xima solicitud de autorizaci\u00f3n de comercializaci\u00f3n (BLA) prevista para el programa de Nanoscope para la RP.<\/p>\n<p><b>T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>Presentaci\u00f3n de Retina (Eyecelerator en AAO 2024)<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">Jueves 17 de octubre<\/span><sup>th<\/sup>, 2024<br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">13:15 \u2013 15:00 CDT<\/span><br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>Centro de convenciones McCormick Place, sala E450a<br class=\"dnr\" \/><b>Presentador:\u00a0<\/b><span class=\"xn-person\">Samuel Barone<\/span>, MD, Director M\u00e9dico<\/p>\n<p>Durante su presentaci\u00f3n, el Dr. Barone mostrar\u00e1 el programa de plataforma de opsina multicaracter\u00edstica de \u00faltima generaci\u00f3n de Nanoscope para pacientes con atrofia geogr\u00e1fica (AG) debida a la degeneraci\u00f3n macular asociada a la edad (DMAE) avanzada. El programa utiliza MCO-020, una terapia g\u00e9nica MCO de \u00faltima generaci\u00f3n, e incorpora el m\u00e9todo patentado de Nanoscope para la administraci\u00f3n de genes mediante tecnolog\u00eda \u00f3ptica, no viral y con focalizaci\u00f3n espacial. El programa de Nanoscope para la AG se encuentra actualmente en la fase previa a un ensayo cl\u00ednico de fase 1\/2 en pacientes con AG.<\/p>\n<p><b>T\u00edtulo de la sesi\u00f3n:\u00a0<\/b>El futuro de la terapia retiniana (Innovate Retina)<br class=\"dnr\" \/><b>Fecha de la sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">17 de octubre<\/span><sup>th<\/sup>, 2024<br class=\"dnr\" \/><b>Tiempo de sesi\u00f3n:\u00a0<\/b><span class=\"xn-chron\">6:24 p.m. CDT<\/span><br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>InterContinental Chicago Magnificent Mile, Gran sal\u00f3n de baile<br class=\"dnr\" \/><b>Miembro del jurado:\u00a0<\/b><span class=\"xn-person\">Samarendra Mohanty<\/span>, PhD, Presidente y Director Cient\u00edfico<\/p>\n<p>El Dr. Mohanty participar\u00e1 en un panel que cubrir\u00e1 el panorama de terapias de vanguardia en desarrollo para abordar enfermedades de la retina.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen y que restauran la visi\u00f3n para los millones de pacientes ciegos por enfermedades degenerativas de la retina, para las cuales no existe cura. El principal activo de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados preliminares del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La empresa ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y recientemente\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">anunci\u00f3 planes para iniciar una Fase 3<\/a>\u00a0Ensayo de registro en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para RP como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0Oct. 15, 2024\u00a0\u2014 Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Nanoscope will present at the\u00a0AAO 2024 Annual Meeting\u00a0taking place\u00a0October 18-21, 2024\u00a0in\u00a0Chicago, Illinois, and the associated\u00a0Eyecelerator @ AAO 2024\u00a0and\u00a0Innovate Retina\u00a0meetings both taking place on\u00a0October 17th, 2024. Details for the presentations are as follows: Title:\u00a0Efficacy and [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5839,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024 - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024 - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T09:10:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:34:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024\",\"datePublished\":\"2024-10-15T09:10:10+00:00\",\"dateModified\":\"2025-06-27T13:34:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/\"},\"wordCount\":486,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_AAOLI_2024._.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/\",\"name\":\"Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024 - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_AAOLI_2024._.jpg\",\"datePublished\":\"2024-10-15T09:10:10+00:00\",\"dateModified\":\"2025-06-27T13:34:47+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_AAOLI_2024._.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_AAOLI_2024._.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/15\\\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope anuncia presentaciones en la Reuni\u00f3n Anual de la Academia Estadounidense de Oftalmolog\u00eda 2024 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024 - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-10-15T09:10:10+00:00","article_modified_time":"2025-06-27T13:34:47+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/09\/NSCOPE_LI_STARGARDTV3.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024","datePublished":"2024-10-15T09:10:10+00:00","dateModified":"2025-06-27T13:34:47+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/"},"wordCount":486,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_AAOLI_2024._.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/","url":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/","name":"Nanoscope anuncia presentaciones en la Reuni\u00f3n Anual de la Academia Estadounidense de Oftalmolog\u00eda 2024 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_AAOLI_2024._.jpg","datePublished":"2024-10-15T09:10:10+00:00","dateModified":"2025-06-27T13:34:47+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_AAOLI_2024._.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_AAOLI_2024._.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/15\/nanoscope-announces-presentations-at-the-american-academy-of-ophthalmology-annual-meeting-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5837"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5837\/revisions"}],"predecessor-version":[{"id":9014,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5837\/revisions\/9014"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5839"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}